SCHEMBL5040340

SCHEMBL5040340

CC(=O)CC(C)c1ccc(C(N)=O)nc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 1/20 0.41
SIRT6 Q8N6T7 2/20 0.39
NNMT P40261 1/20 0.37
FFAR1 O14842 2/20 0.36
STAT3 P40763 1/20 0.36
P4HTM Q9NXG6 1/20 0.35
APP P05067 1/20 0.35
ACHE P22303 1/20 0.35
NAMPT P43490 1/20 0.35
PDE4A P27815 1/20 0.34
PDE4B Q07343 1/20 0.34
PDE4C Q08493 1/20 0.34
PDE4D Q08499 1/20 0.34
VNN1 O95497 1/20 0.34
HRH3 Q9Y5N1 2/20 0.33
TLR8 Q9NR97 1/20 0.33
TLR7 Q9NYK1 1/20 0.33
ESR1 P03372 1/20 0.33
ESR2 Q92731 1/20 0.33
GRM2 Q14416 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2677914 0.84 ALDH1A1 (0.44) KMT2ASIRT6P4HTM
SCHEMBL6468851 0.81 KMT2A (0.41) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL6469092 0.81 KMT2A (0.41) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL5040341 0.81 CPB2 (0.42) NNMTFFAR1STAT3ACHE
SCHEMBL8953636 0.80 KMT2A (0.49) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL6469006 0.78 KMT2A (0.47) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL6469024 0.78 KMT2A (0.39) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL6650658 0.76 KMT2A (0.45) KMT2ASIRT6NNMTP4HTMAPP
SCHEMBL6370728 0.75 PARP10 (0.46) KMT2AFFAR1STAT3ACHEVNN1
SCHEMBL5040582 0.74 KMT2A (0.35) KMT2ASIRT6P4HTMAPPNAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1654260-A4 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-09-24 EP claimed
EP-1654260-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP claimed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 WO claimed
EP-1654260-A4 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PROD INC (US) 2008-09-24 EP disclosed
EP-1654260-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS Pfizer Products Inc. (US) 2006-05-10 EP disclosed
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders PFIZER, INC. 2005-05-19 US disclosed
WO-2005011601-A2 6-MENBERED HETEROARYL COMPOUNDS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS PFIZER PRODUCTS, INC. (US) 2005-02-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050107381-A1 6-membered heteroaryl compounds for the treatment of neurodegenerative disorders APP, BACE1, SNCA KMT2A 2085/4885SIRT6 750/4885NNMT 559/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.